Kornimate/medical-research-clean huggingface dataset:
tele-anesthesia - trans-continental anesthesia compared to standard practice

Conditions: Thyroid Gland Resection

Summary: patients in pisa will undergo thyroid gland surgery. in the protocol group anesthesia will be performed using an automated anesthesia delivery system; preoperative and intra-operative assessment of patients will be performed via video-conferencing from montreal, which will also monitor and control anesthesia delivery via distant internet connection - as supervision of functioning of the automated anesthesia delivery system. in the control group anesthesia will be performed in a standard fashion with manual control of the syringe pumps infusing anesthetics drugs. the hypothesis is that tele-anesthesia, considered as preoperative assessment and anesthetic control of an automated anesthesia delivery system is feasible and reliable via standard means of internet communication (distant control via virtual network) and performed as well or even better than manual control of the anesthetic drugs infusion.


Eligibility criteria:
inclusion criteria: * elective patients * patient scheduled for surgery under spinal anesthesia * patients aged 18 to 85 years exclusion criteria: * unable to provide informed consent * comatose patients * patients with dementia * allergy to propofol

Keywords: thyroid gland resection surgery total intravenous anesthesia
association of copy number variations in the smn genes with acute kidney injury after heart surgery

Conditions: Acute Kidney Injury

Summary: this prospective cohort study aims to explore the susceptibility to acute kidney injury after heart surgery in smn1+/- genotype population. this study also aims to analysis the effect of smn1+/- genotype on postoperative aki and the development of chronic kidney disease, as well as dose-compensating effect of different copy number of smn2 gene on smn1 +/- genotype.

this prospective cohort study aims to explore the susceptibility to acute kidney injury after heart surgery in smn1+/- genotype population. real-time pcr is used to detect copy number variations in the peripheral blood smn gene on 1206 patients with heart surgery. this study also aims to analysis the effect of smn1+/- genotype on postoperative aki and the development of chronic kidney disease, as well as dose-compensating effect of different copy number of smn2 gene on smn1 +/- genotype.

Eligibility criteria:
inclusion criteria: * age: children (1 month -17 years old) and adults (18-80 years old); * sex: all; * those who will receive selective cardiac surgery with cardiopulmonary bypass; * those who signed the informed consent. exclusion criteria: * those with glomerular filtration rate: egfr\<15ml/min/1.73m2, and those who have received the renal replacement therapy before surgery; * those who have received nephrectomy and kidney transplantation; * those who have suffered from aki before; * those with incomplete medical history or clinical data.
coolsculpting of the flank with alternate treatment parameters

Conditions: Body Fat Disorder

Summary: the purpose of this study is to evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction with an alternative treatment parameter.

the study evaluated the use of the zeltiq coosculpting system for non-invasive fat removal in the flank.

Eligibility criteria:
inclusion criteria 1. male or female subjects \> 18 years of age and \< 65 years of age. 2. subject has clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment. 3. subject has not had weight change exceeding 10 pounds in the preceding month. 4. subject with body mass index (bmi) up to 30. bmi is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. 5. subject agrees to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study. 6. subject has read and signed a written informed consent form. exclusion criteria 1. subject has had a surgical procedure(s) in the area of intended treatment. 2. subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. 3. subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months. 4. subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. 5. subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. 6. subject has a known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. 7. subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. 8. subject is taking or has taken diet pills or supplements within the past month. 9. subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). 10. subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system 11. subject is pregnant or intending to become pregnant during the study period (in the next 5 months). 12. subject is lactating or has been lactating in the past 6 months. 13. subject has a history of hernia in the areas to be treated. 14. subject is unable or unwilling to comply with the study requirements. 15. subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 16. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Keywords: lipolysis cryolipolysis fat reduction
effects and interactions of liquorice and grapefruit on glucocorticoid replacement therapy in addison's disease

Conditions: Addison Disease

Summary: addison's disease is a rare disease, wherein the adrenals can not produce sufficient steroid hormones (cortisol and aldosterone). patients with addison's disease report impaired subjective health status, and they have increased all-cause mortality. conventional therapy is by oral replacement of glucocorticoid and mineralocorticoid hormones, but this strategy imperfectly mimic the diurnal cortisol variations, and render the patients both over- and under-treated. anecdotally, some patients with adrenal insufficiency may benefit from the use of various nutritional compounds. we hypothesised that liquorice and grapefruit altered the metabolism and absorption of cortisone acetate.

in the present study, cortisone acetate absorption and metabolism are assessed in subjects with addison's disease on three occasions. on the first occasion, the subjects are on their regular diet, but avoid ingestion of grapefruit and liquorice. at the end of the baseline assessment the order of the nutritional compounds (liquorice-grapefruit juice or grapefruit juice-liquorice) to be investigated in the next two assessments are randomised. on the two next occasions, the absorption and metabolism of cortisone acetate is studied when study subjects consume liquorice and grapefruit juice. between the use of grapefruit and liquorice there is a wash out period of at least 3 weeks. for studies on liquorice effects, the subjects ingest 24-gram liquorice per day (equivalent of 150-mg glycyrrhizinic acid per day). for studies on grapefruit juice effects, subjects drink 200-ml grapefruit juice three times a day for three days. they maintain their regular medication and usual diet. time-series of cortisol and cortisone are obtained in serum and saliva samples on the third day of liquorice/grapefruit juice use. 24-hour urine is also collected. measurements of cortisol and metabolites in serum and saliva are used to calculate pharmacokinetical parameters. the measurements from samples obtained when using the investigated nutritional compounds are compared to the baseline assessment in each subject. metabolites in 24-hour urine are compared similarly to investigate changes in urinary excretion, and to estimate the activity of enzymes involved in the metabolism of cortisol (5alfa-reductase, 5beta-reductase, cytochrome p450 3a4 system, 11-beta hydroxysteroid dehydrogenase).

Eligibility criteria:
inclusion criteria: * verified diagnosis of adrenal insufficiency (addison's disease) * stable cortisone acetate replacement therapy * written informed consent exclusion criteria: * malignant disease * pharmacological treatment with other glucocorticoids * pregnancy * current minor disease (ie the flu) * major disease or accident requiring hospitalization the last three months * use of grapefruit juice or liquorice the last two weeks before study start * blood pressure above 150mmhg systolic or 90 mmhg diastolic.

Keywords: addison disease pharmacokinetics hormone replacement therapy cortisone acetate quality of life
safety and efficacy of rotational atherectomy (ra) in coronary dissection

Conditions: Coronary Artery Disease

Summary: this study is aimed at examining the safety and efficacy of rotational atherectomy (ra) in nondilatable calcified lesion complicated by coronary dissection during percutaneous coronary intervention (pci) procedure.

coronary artery dissection is a contraindication for the use of rotational atherectomy, since rotational atherectomy may propagate coronary dissection. in the presence of coronary dissection, conservative management is suggested for approximately 4 weeks to permit the dissection to heal prior to treatment with rotational atherectomy. however, a lot of patients have frequent angina attacks and some patients develop serious complications including abrupt vessel closure during this period. thus, immediate strategies cope with coronary dissection induced by balloon dilation is needed for the early recovery of those patients. the present study was performed to compare the safety and efficacy of immediate ra and delayed ra in the treatment with nondilatable calcified lesion complicated by coronary dissection.

Eligibility criteria:
inclusion criteria: * age between 30 and 85 years old * nondilatable calcified lesion complicated by coronary dissection during percutaneous coronary intervention (pci) procedure * coronary artery dissection type a, b and type c according to the national heart, lung and blood institute (nhlbi) coronary dissection criteria exclusion criteria: * acute myocardial infarction * unprotected left main stenosis * chronic total occlusion * saphenous vein graft lesion * cardiomyopathy * severe valvular heart disease * nyha functional class iv heart failure at baseline * chronic renal failure on hemodialysis * severe lung and liver disease or cancer

Keywords: rotational atherectomy coronary dissection percutaneous coronary intervention calcification
evaluation of igm-2644 in adults with relapsed and/or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of igm-2644 as a single agent in participants with relapsed and/or refractory mm, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a rp2d. the total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.

patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage. the escalation stage will investigate single agent igm-2644 safety and tolerability in patients with relapsed and/or refractory multiple myeloma. the dose expansion cohort(s) will further evaluate safety, pk/pd, and preliminary efficacy of the recommended phase 2 dose (rp2d). igm-2644 will be administered intravenously (iv).

Eligibility criteria:
inclusion criteria: * adults \> 18 years at time of consent * ecog performance status of 0 or 1 * relapsed and/or refractory multiple myeloma after ≥ 3 prior lines; must have failed treatment with an imid, pi, and anti-cd38 therapy * measurable disease per the imwg response criteria * adequate marrow and organ function without transfusion or growth factor support within 7 days prior to screening * willing and able to undergo bone marrow aspirate and biopsy per protocol exclusion criteria: * inability to comply with study and follow-up procedures * history of clinically significant primary amyloidosis, plasma cell leukemia, waldenstrom macroglobulinemia or myelodysplastic syndrome * received chemotherapy, biologics, or small molecule therapy within 21 days or 5 half-lives, whichever is shorter * use of any non-approved or investigational agent ≤ 4 weeks prior to the first dose of study drug. * received last prior anti-cd38 monoclonal antibody treatment within 28 days before first planned dose of the study drug * current grade \> 1 toxicity, with the exception of grade 2 peripheral neuropathy, alopecia, or toxicities from prior anti-tumor therapy that are considered irreversible * large-field radiotherapy within 28 days prior to day 1 (radiation to a single site as concurrent therapy is allowed) * prior autologous stem cell transplant within 180 days prior to day 1 * prior allogeneic stem cell transplant

Keywords: relapsed and/or refractory relapsed/refractory multiple myeloma cd38 anti-cd3 immunotherapy monoclonal antibodies bispecific t-cell engager
oral progesterone for prevention of preterm birth

Conditions: Preterm Birth

Summary: to evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (rspb) and whether micronized progesterone use increases maternal serum progesterone levels.

to evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (rspb) and whether micronized progesterone use increases maternal serum progesterone levels.

Eligibility criteria:
inclusion criteria: * pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation. exclusion criteria: * multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.

Keywords: preterm birth, prevention, progesterone, oral
dexmedetomidine and midazolam nebulization as sedation during cesarean delivery in pre-eclampsia

Conditions: Procedural Sedation

Summary: null hypothesis: there is no difference between the effects of nebulization of dexmedetomidine and midazolam as procedural sedation during cesarean delivery under spinal anesthesia in pre-eclamptic parturients alternative hypothesis: there is difference between the effects of nebulization of dexmedetomidine and midazolam as procedural sedation during cesarean delivery under spinal anesthesia in pre-eclamptic parturients

site of study: this study will be carried out in operating theater of obstetrics at zagazig university hospitals. withdrawal criteria: the woman has the right to withdraw from the study at any time without any negative consequence on their medical or surgical treatment plan. double -blind randomized clinical trial. all patients will be hospitalized and visited a day before the surgery, full history with physical examination and routine investigation will be done, the nature and complications of the study will be explained in detail to the patient and informed written consent will be obtained from every woman.

Eligibility criteria:
inclusion criteria: * age: 21-38 years old. * mild and moderate preeclampsia parturient. * american society of anesthesiologistphysical status ii. * body mass index (bmi) (25-35kg/m²). * type of operations: elective cesarean section under spinal anesthesia. * written informed consent from the parturient. exclusion criteria: * altered mental state. * women with known history of allergy to study drugs. * women with uncontrolled diabetes mellitus, bleeding, coagulation disorders, advanced hepatic, renal, cardiovascular, respiratory disease and neuropsychiatric disorders. * patients receiving anticonvulsants or antidepressants. * sever preeclampsia, intrauterine growth restriction or fetal compromise.
evaluation of the safespace app intervention

Conditions: Health Behavior; Health Care Utilization; Unprotected Sex; Sexually Transmitted Infections

Summary: the goal of this study is to evaluate the impact of safespace sexual health app, an innovative sexual health promotion program focused on reducing sexual risk factors and promoting sexual and reproductive health and wellbeing among young people assigned female or intersex at birth, particularly black and/or latine youth, lgbtq+ youth, youth in states with high teen birth rates and youth who live in rural communities. this study utilizes a two-arm randomized control trial design to measure impacts of receiving the safespace sexual health program compared to receiving a similar-length control app program, safespace general health that focuses on general health. the investigators will ask participants to: * keep the safespace app downloaded to their device and visit the app regularly over the course of 10 weeks. * provide contact information. * receive and open app push notifications for 10 weeks (up to 3 per week). * complete 3 online surveys over a year: baseline, short-term follow-up (10 weeks after baseline), and long-term follow up (9 months after short-term follow-up). * receive occasional text messages from the study team.


Eligibility criteria:
inclusion criteria: * participants must be assigned female or intersex at birth * participants must be youth in the u.s. (14-18 years old) * participants must have daily access to an iphone exclusion criteria: - participants must not be currently pregnant or currently trying to become pregnant other criteria: - the study's priority/preference population is for black and/or latine youth, lgbtq+ youth, youth from geographic areas with high teen birth rates, and youth living in rural areas.
intervention toward truth-telling and advanced directives in the patient with advanced or metastatic disease

Conditions: Advanced Cancer; Metastatic Cancer

Summary: family usually had a lot of burden to tell the truth to patients. the purpose of this study is to assess the effect of education materials and family conference for advanced cancer patients and family.


Eligibility criteria:
inclusion criteria: * advanced or metastatic cancer patients * more than 20 years old * clear consciousness and be able to communicate exclusion criteria: * refuse to know the statement of himself/herself disease
promoting gastrointestinal health and reducing subclinical inflammation in obese individuals

Conditions: Obesity; Overweight

Summary: this study evaluates the impact of increased intake of fruits and vegetables and whole grains on markers of inflammation and gut microbial composition. the treatment groups are 3 servings of whole grain per day; 5 servings of fruits and vegetables per day; and a control (3 servings of refined grains per day provided).

literature data suggests that fruits and vegetables and whole grains containing dietary fiber and other nutrients are important for maintaining beneficial microbes in the gut. the presence of beneficial microbes in the gut may mediate the subclinical inflammation experienced in metabolic disease. in this project, overweight or obese participants with low intakes of fruits and vegetables or whole grains will increase their intake of these foods to recommended levels. changes in markers of inflammation and gut microbiota composition will be determined to assess and compare the potential impact of these foods on metabolic disease.

Eligibility criteria:
inclusion criteria: * obese or overweight men or women (body mass index, bmi, ≥25 kg/m2) * free of known gastrointestinal disease * no supplements use (excluding multivitamin) * participate in less than 1 h of exercise per week * have not taken antibiotics in the last six months exclusion criteria: * men and women with fruits and vegetable intake exceeding 2 servings/day * men and women with whole grain intakes exceeding 1 serving/day * pregnant * do not fit the inclusion criteria

Keywords: diet whole grain fruits vegetables gut health anti-inflammatory
efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine

Conditions: Migraine With or Without Aura

Summary: to confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.


Eligibility criteria:
inclusion criteria: * history of at least one typical attack of migraine with or without aura every 6 weeks, as defined by the international headache society (ihs) criteria. * capable of taking study medication as outpatients and recording its effects. exclusion criteria: * pregnant or breast-feeding women * migraine subjects who also suffered from concomitant frequent (non-migraine) headache, defined as more than six headaches per month on average * migraine attacks that were thought to be atypical and had consistently failed to respond to medical therapy.
expert learning in musculoskeletal ultrasound

Conditions: Musculoskeletal Diseases

Summary: musculoskeletal ultrasound (msus) is a complex procedure and requires lifelong theoretical and practical training to ensure continued professional development. currently, the teaching approach for experts in msus is theoretical preparation first and then hands-on training, the "tell-then-do" approach. the existing literature on optimizing training for experts is sparse, and it is unknown if the training intervention discovery learning could be a more effective teaching method for this group of learners.


Eligibility criteria:
inclusion criteria: * experts in msus, defined as physicians who have performed more than 1000 msus examinations exclusion criteria: * physicians who have not performed 1000 msus examinations.

Keywords: medical education ultrasound
evaluation of number of patient eyes that remained on or switched to anti-vegf treatment after initiation of broluciumab

Conditions: Age-related Macular Degeneration (AMD)

Summary: this was a retrospective cohort study to assess the treatment history, demographic characteristics, clinical characteristics, and early treatment patterns of patients who received brolucizumab for neovascular age-related macular degeneration using iris registry.

this was a retrospective cohort study of patients with wet amd who received brolucizumab. evidence was generated from the iris registry to describe patient treatment histories, demographic and clinical characteristics, and early treatment patterns. setting and study population: iris registry ehr data from 10/08/2018 to the 03/31/2020 from patients with wet amd who initiated brolucizumab were analyzed. identification period of the index date: the patients fulfilling the selection criteria identified during the period from 10/08/2019 to 03/31/2020. index date: defined as the date of the earliest brolucizumab injection. study period: the period from 10/08/2018 to 03/31/2020. pre-index period: the period 12 months prior to the index date. post-index period: the period 4 months after the index date (not a required selection criterion; only for the assessment of select endpoints in a subgroup of patients).

Eligibility criteria:
inclusion criteria: * patients with ≥1 brolucizumab injection * diagnosis of wet amd (icd-10: h35.3210, h35.3211, h35.3212, h35.3213, h35.3220, h35.3221, h35.3222, h35.3223, h35.3230, h35.3231, h35.3232, h35.3233, h35.3290, h35.3291, h35.3292, and h35.3293) on the index date exclusion criteria: * there were no exclusion criteria

Keywords: amd, brolucizumab, anti-vegf switchers, treatment-naive